Browse result page of AntiTbPdb
The total number entries retrieved from this search are 68
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1576 | Protegrin -1 | RGGRLCYCRRRFCVCVGR | Free | Free | Disulphide linkage 6-15 and 8-13 | Cyclic | 21 | L | Cationic | Natural | Derived from porcine leucocyte | Mycobacterium tuberculosis | Mycobacterium tuberculosis RM25 | CFU/well 3.19 ± 0.05 at peptide concentration 4 μg/ml +INH 4μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2004 | 15245864 |
| antitb_1577 | Protegrin -1 | RGGRLCYCRRRFCVCVGR | Free | Free | Disulphide linkage 6-15 and 8-13 | Cyclic | 22 | L | Cationic | Natural | Derived from porcine leucocyte | Mycobacterium tuberculosis | Mycobacterium tuberculosis RM26 | CFU/well 3.08 ± 0.09 at peptide concentration 64 μg/ml +INH 4μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Bacterial membrane pore formation | NA | NA | NA | 2004 | 15245864 |
| antitb_1737 | FKAB-1F | KL-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-KR | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 21 | L | Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae | MIC = 30 μM | Both | RBC | NA | 63 % hemolysis at 100 and 25 μM | Mice | NA | NA | NA | NA | None | Anti-bacterial (Salmonella typhimurium, Staphylococcus aureus, Bacillus subtillis) | 2012 | US 2012/0197004 |
| antitb_1778 | Peptide-22 | KL-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-KR | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 21 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 93 µg/mL | Both | RBC | NA | 63 % hemolytic activity at 100 µM peptide | mouse skin wound healing model | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1808 | Ci-MAM-A24 | WRSLGRTLLRLSHALKPLARRSGW | Free | Amidation | None | Linear | 24 | L | Cationic | Protein Derived | Derived from immune cells of Ciona intestinalis, | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 | 45% bacterial population was killed at 10 μM peptide incubated for 1 hr | In vitro | mouse macrophage RAW 264.9 | NA | Slight toxic (two-fold decrease in cell viability was observed at 50 μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21396418 |
| antitb_1809 | Ci-MAM-A25 | WRSLGRTLLRLSHALKPLARRSGW | Free | Amidation | None | Linear | 24 | L | Cationic | Protein Derived | Derived from immune cells of Ciona intestinalis, | Mycobacterium bovis | Mycobacterium bovis BCG Pasteur (ATCC35734) | After 24 h, more than 78% killing was observed at 30 μM | In vitro | mouse macrophage RAW 264.10 | NA | Slight toxic (two-fold decrease in cell viability was observed at 50 μM | NA | NA | NA | NA | NA | NA | NA | 2011 | 21396418 |
| antitb_1872 | Transportan | AGYLLGKINLKALAALAKKIL | Free | Free | None | Linear | 21 | L | Cationic | Synthetic | Constructed from Galanin and Mastoparan proteins | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC = 80 μM | In vitro | RBC | NA | 50% hemolysis at 38.0 ± 3.79 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
| antitb_1873 | Magainin | GIGKFLHSAKKFGKAFVGEIMNS | Free | Free | None | Linear | 23 | L | Cationic | Natural | Peptide from Xenopus laevis skin | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
| antitb_1875 | GranF2 | VCRTGRSRWRDVCRNFMRRYQSR | Free | Free | None | Linear | 23 | L | Cationic | Protein Derived | Peptide derived from Granulysin protein | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
| antitb_1881 | Polydim-I | AVAGEKLWLLPHLLKMLLTPTP | Free | Free | None | Linear | 22 | L | Amphipathic | Natural | Isolated from the venom of the Neotropical wasp Polybia dimorpha | Mycobacterium abscessus | Mycobacterium abscessus subsp. massiliense isolates GO 01, GO 06, GO 07, GO 08, GO 13, and GO 18, CRM0020 (Mycobacterium abscessus subsp. massiliense), and ATCC19977 (Mycobacterium abscessus subsp. abscessus) | MIC = 60.8 μg/mL | Both | Peritoneal macrophages, J774 macrophages cells, human red blood cells | Treatment of infected macrophages with 7.6 μg/mL of Polydim-I decreased approximately 50% of the bacterial load | Non-cytotoxic, 10% cytotoxicity on J774 cells at concentrations above 121.6 μg/mL (10%) and concentrations up to 121.6 μg/mL presented less than 2.5% of hemolytic activity | 6 to 8 weeks old BALB/c and IFN-γKO (Knockout) female mice | 2 mg/kg/mLW shows 90% reduction in bacterial load | NA | Cell wall disruption | Cell wall | None | NA | 2016 | 26930596 |
| antitb_1916 | Peptide-1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, | Linear | 22 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC =4.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1927 | Peptide-1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, | Linear | 22 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | MIC =4.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1938 | Peptide-1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Acetylation | Amidation | A6c = 1-aminocyclohexane carboxylic acid, | Linear | 22 | D | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR | MIC =4.92 μM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall pore formation | NA | Antibacterial against Enterobacter aerogenes, Acinetobacter baumannii, Psuedomonas aeruginosa, Klebsiella pneumoniae, Eenterococcus faecalis, Staphylococcus aureus | 2016 | 27387357 |
| antitb_1987 | TP10 | AGYLLGKINLKALAALAKKIL | Free | Amidation | None | Linear | 21 | L | NA | Synthetic | NA | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC=6µM | In vitro | HeLa cells | NA | NA | NA | NA | NA | NA | cell wall | NA | Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Bacillus subtilis, Candida albicans etc. | 2003 | 14656995 |
| antitb_1994 | VpAmp2.0 | FWGFLGKLAMKAVPSLIGGNKSSSK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC= 21.4 ± 7.5 µM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall | NA | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae | 2015 | 26352292 |
| antitb_1995 | VpAmp2.0 | FWGFLGKLAMKAVPSLIGGNKSSSK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | MIC= 30.5 ± 9.5 µM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall | NA | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae | 2015 | 26352292 |
| antitb_1996 | VpAmp2.1 | FWGFLGKLAMKAVPSLIGGNKK | Free | Free | None | Linear | 22 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC= 13.6 ± 5.3 µM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall | NA | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae | 2015 | 26352292 |
| antitb_1997 | VpAmp2.1 | FWGFLGKLAMKAVPSLIGGNKK | Free | Free | None | Linear | 22 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR | MIC= 8.5 ± 2.6 µM | In vitro | NA | NA | NA | NA | NA | NA | NA | Cell wall | NA | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae | 2015 | 26352292 |